LUNSUMIO SC DIN 02567377
Status: Marketed
Holder: HOFFMANN-LA ROCHE LIMITED
Health Canada record
| Active ingredient(s) | MOSUNETUZUMAB 45 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | L01FX25 MOSUNETUZUMAB |
|---|
| Original market date | 16-Jun-2026 |
|---|
| Current status date | 16-Jun-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MOSUNETUZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02565226 | LUNSUMIO | HOFFMANN-LA ROCHE LIMITED | Solution | MOSUNETUZUMAB 1 MG | Marketed |
| 02567369 | LUNSUMIO SC | HOFFMANN-LA ROCHE LIMITED | Solution | MOSUNETUZUMAB 5 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 37489 | 2026-04-10 | New Drug Submission (NDS) | |
Request a quote for LUNSUMIO SC
How to read a Canadian DIN record